Medtronic PLC (MDT) to Issue Quarterly Dividend of $0.71 on April 17th

Medtronic PLC (NYSE:MDT) declared a quarterly dividend on Thursday, March 5th. Shareholders of record on Friday, March 27th will be paid a dividend of 0.71 per share by the medical technology company on Friday, April 17th. This represents a c) annualized dividend and a yield of 3.1%. The ex-dividend date is Friday, March 27th.

Medtronic has raised its dividend by an average of 0.1%per year over the last three years and has increased its dividend every year for the last 49 years. Medtronic has a payout ratio of 47.2% meaning its dividend is sufficiently covered by earnings. Equities analysts expect Medtronic to earn $5.83 per share next year, which means the company should continue to be able to cover its $2.84 annual dividend with an expected future payout ratio of 48.7%.

Medtronic Price Performance

MDT opened at $90.83 on Friday. The company has a market capitalization of $116.61 billion, a P/E ratio of 25.30, a PEG ratio of 2.34 and a beta of 0.71. The company has a 50-day moving average of $98.69 and a 200-day moving average of $96.94. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54. Medtronic has a 1-year low of $79.55 and a 1-year high of $106.33.

Medtronic (NYSE:MDT) last issued its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, topping the consensus estimate of $1.34 by $0.02. The business had revenue of $9.02 billion for the quarter, compared to analysts’ expectations of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The company’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter last year, the company posted $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities analysts expect that Medtronic will post 5.46 EPS for the current fiscal year.

Insider Buying and Selling at Medtronic

In related news, EVP Harry Skip Kiil sold 52,524 shares of the firm’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total value of $5,132,120.04. Following the sale, the executive vice president owned 32,768 shares of the company’s stock, valued at approximately $3,201,761.28. This trade represents a 61.58% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.26% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in MDT. Delos Wealth Advisors LLC bought a new position in shares of Medtronic during the second quarter worth about $27,000. Corundum Trust Company INC bought a new stake in Medtronic in the 3rd quarter valued at about $27,000. Lodestone Wealth Management LLC acquired a new position in Medtronic during the 4th quarter worth $27,000. Anfield Capital Management LLC lifted its stake in shares of Medtronic by 410.7% in the 4th quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 230 shares during the period. Finally, Monetary Solutions Ltd bought a new position in shares of Medtronic during the 4th quarter valued at about $27,000. 82.06% of the stock is currently owned by institutional investors.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).